Skip to content
Back to Investors
IQ Capital

IQ Capital

Venture Capital

IQ Capital specialises in backing IP-rich technology businesses with a track record of stable growth.


Recent investments

Seed
$21.5M

The seed round was led by EQT Ventures to support team growth and the development of full-stack robotics solutions.

"Physics simulation is fundamental to many sectors, such as research, manufacturing, and robotics. With decades of expertise in physics simulation technology, Michelle and Kier have built a solution that offers 100x performance for the fraction of the cost, helping users achieve breakthroughs in their fields."
— Sandra Malmberg, Partner
Seed
£2.1M

The round was co-led by IQ Capital and Mundi Ventures to support team expansion and product development.

"Synthesized substantially reduces the time to develop and comprehensively test data-driven projects and as a result empowers engineers to build better products and services for end users. With the new funding from IQ Capital and Mundi Ventures, Synthesized is well-positioned to facilitate its business operations to turbocharge development processes across many sectors, such as finance, insurance and healthcare. We will continue to double down on bringing the highest quality data infrastructure to our clients and partners."
— Nicolai Baldin, Founder and CEO
Seed
£8.5M

Mercia Ventures and BGF led the Series A round to help the biotechnology firm commercialise its RNA sequencing technology.

"Genetic sequencing has come a long way since its inception in the 1970’s. The industry is now moving past short-read towards long-read sequencing, with long-read RNA sequencing being one of the most exciting new developments in biotechnology. We believe our solution could accelerate a new wave of biotechnology innovations. We are pleased to receive backing from some of the UK’s leading life science investors, which highlights its potential. The funding will help us to pursue our mission to reveal the unseen world of RNA and unlock exciting new applications."
— Richard Kuo, CEO
Series A
£15.0M

The round was led by Buckley Ventures and will fund manufacturing and distribution scale-up.

"The most tedious process in biotech is growing human cells by hand. Every scientist needs to spend hours a day growing cells and coming in on weekends to look after them,"
— Ali Afshar, CEO & Co-Founder
Seed
£7.0M

The pre-series A round was led by Amadeus Capital Partners, Expeditions Fund, and IQ Capital.

"Large-scale, fault-tolerant quantum computing will bring about the technological revolution of our generation. We have built an exceptional team dedicated to the mission of building the quantum networking infrastructure necessary to make this a reality. We are grateful to the investors who share our vision for their support as we scale and commercialise our solution."
— Carmen Palacios, Founder and CEO